Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
- PMID: 23807848
- PMCID: PMC3686240
- DOI: 10.2147/NDT.S43574
Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
Abstract
Background: This study identified subgroups of patients with schizophrenia who differed on their movement disorder profile and compared their treatment outcomes.
Methods: Data from a randomized, open-label, one-year study of patients with schizophrenia who were treated with antipsychotics in usual clinical care settings were analyzed (n = 640). Five measures of movement disorder were incorporated into a single Movement Disorder Index (MDI). Subgroups that differed in their movement disorder profile over the one-year study period were compared on clinical and functional outcomes.
Results: THREE SUBGROUPS WERE IDENTIFIED: a worsening of MDI in 15% of patients, an improvement in 33%, and no change in 53%. Compared with the other two subgroups, the MDI-worsened subgroup had poorer symptom improvement measured by the Positive and Negative Syndrome Scale (PANSS) total score (mean changes of -11.0, -18.4, and -16.8 for the patients who had a worsening of MDI, no change, and an improvement, respectively), poorer symptom improvement on the PANSS positive and anxiety/depression subscale scores, worsening on the 36-Item Short Form Health Survey (SF-36) physical component summary score, and a higher rate of hospitalization (P < 0.05).
Conclusion: Patients with schizophrenia who experience worsening of their MDI score appear to have poorer clinical and functional outcomes, suggesting that such worsening may be a marker of poorer prognosis.
Keywords: movement disorder; schizophrenia; treatment outcome.
Figures
Similar articles
-
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.J Clin Psychiatry. 2002 Oct;63(10):931-5. doi: 10.4088/jcp.v63n1011. J Clin Psychiatry. 2002. PMID: 12416603 Clinical Trial.
-
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.J Clin Psychiatry. 2007 Mar;68(3):368-79. doi: 10.4088/jcp.v68n0303. J Clin Psychiatry. 2007. PMID: 17388705 Clinical Trial.
-
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.J Clin Psychiatry. 2004 Dec;65(12):1624-33. doi: 10.4088/jcp.v65n1207. J Clin Psychiatry. 2004. PMID: 15641867 Clinical Trial.
-
Paliperidone extended release: a review of its use in the management of schizophrenia.Drugs. 2010 Jul 9;70(10):1295-317. doi: 10.2165/11204840-000000000-00000. Drugs. 2010. PMID: 20568835 Review.
-
Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.Health Technol Assess. 2005 Nov;9(42):1-174. doi: 10.3310/hta9420. Health Technol Assess. 2005. PMID: 16266559 Review.
References
-
- Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13:13–24. - PubMed
-
- Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull. 1984;20:387–389. - PubMed
-
- Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54:133–139. - PubMed
-
- Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999;156:309–311. - PubMed
-
- Beasley CM, Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996;124:159–167. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources